Nu Skin Enterprises Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Nu Skin Enterprises Inc in the second quarter 2026?
Nu Skin Enterprises Inc recorded a cumulative net loss of $-216 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -29.42%.

Within the Pharmacy Services & Retail Drugstore industry 3 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 1753 to 1778.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-31.1 %	5.32 %	23.61 %	13.15 %	-
Y / Y Net Income Change	-	-98.29 %	-	105.72 %	-
Net Income (TTM) in Millions	-216	55	160	110	101
Return On Equity (TTM)	-29.42 %	6.84 %	20.36 %	14.65 %	13.91 %
NUS's Total Ranking	# 1778	# 1753	# 469	# 510	# 528
Equity (TTM) in Millions	543	794	805	800	788
Seq. Equity Change	-31.65 %	-1.39 %	0.68 %	1.53 %	4.48 %
Seq. Net Income Change	-	-87.33 %	-15.15 %	-19.13 %	-80.36 %

Back to NUS Management Effectiveness >> NUS's 5 Years Annual ROE >> Compare NUS ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 4
Sector	# 128
Overall	# 1778

Return On Equity Statistics
High	Average	Low
50.16 %	17.64 %	-29.42 %
(Dec 31 2013)		(Jun 30 2026)

NUS Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	805	651	822	897	913
Y / Y Equity Change	23.61 %	-20.74 %	-8.4 %	-1.7 %	2.07 %
Net Income in Millions	160	-147	9	105	147
Y / Y Net Income Change	-	-	-91.8 %	-28.85 %	-23.04 %
Return On Equity	19.9 %	-22.5 %	1.05 %	11.68 %	16.13 %

Back to NUS Management Effectiveness >> NUS's 5 Years Annual ROE >> Compare NUS ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 19.9 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Pharmacy Services & Retail Drugstore Industry Roe Trends and Statistics
Retail Sector Return On Equity Statistics
NUS's' Return on Equity at Yahoo Finance
NUS's Roe Ratio versus Pharmacy Services & Retail Drugstore Industry, Retail Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NUS's Competitors
Subscribers only: Roe for Nu Skin Enterprises Inc 's Suppliers
Subscribers only: Return On Equity for NUS's Customers

Companies with similar Return On Equity at Jun 30 2026, within Retail Sector

ROE

Date modified: 2026-09-12T06:18:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.